Biosergen AS (ST:BIOSGN) — Stock Price
Biosergen AS (ST:BIOSGN) is currently trading at Skr2.02 SEK, down 27.34% today. Over the past 52 weeks, shares have ranged between Skr0.43 and Skr50.40. This page tracks Biosergen AS's live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see BIOSGN company net worth.
Biosergen AS (BIOSGN) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Biosergen AS's daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.
Biosergen AS Income Statement — Revenue, Profit & Earnings by Year
Biosergen AS's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 | Skr8.57 Million |
| Cost of Revenue | Skr0.00 | Skr0.00 | Skr456.00K | Skr280.00K | Skr178.00K |
| Gross Profit | Skr0.00 | Skr0.00 | Skr-456.00K | Skr-280.00K | Skr-178.00K |
| Research & Development | — | — | — | — | — |
| SG&A | — | — | — | — | Skr40.64 Million |
| Total Operating Expenses | Skr40.86 Million | Skr20.69 Million | Skr26.81 Million | Skr33.85 Million | Skr33.90 Million |
| Operating Income | Skr-40.86 Million | Skr-20.69 Million | Skr-27.27 Million | Skr-34.13 Million | Skr-34.08 Million |
| EBITDA | — | Skr-19.20 Million | Skr228.00K | Skr-39.99 Million | Skr-34.08 Million |
| EBIT | — | — | Skr-27.04 Million | Skr-34.13 Million | Skr-34.08 Million |
| Interest Expense | — | Skr78.00K | Skr9.00K | Skr54.00K | Skr240.00K |
| Income Before Tax | Skr-40.82 Million | Skr-19.20 Million | Skr-27.04 Million | Skr-34.05 Million | Skr-34.32 Million |
| Income Tax Expense | — | — | Skr34.75 Million | Skr-135.00K | Skr240.00K |
| Net Income | Skr-40.82 Million | Skr-19.20 Million | Skr-27.04 Million | Skr-34.05 Million | Skr-34.56 Million |
Biosergen AS Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Biosergen AS's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Skr21.16 Million | Skr52.85 Million | Skr7.20 Million | Skr33.79 Million | Skr29.49 Million |
| Total Current Assets | Skr21.57 Million | Skr52.85 Million | Skr7.20 Million | Skr33.79 Million | Skr29.49 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | Skr6.21 Million | Skr1.95 Million | Skr4.93 Million | Skr4.02 Million | Skr3.17 Million |
| Inventory | — | — | Skr-4.93 Million | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Skr13.04 Million | Skr3.71 Million | Skr5.08 Million | Skr11.00 Million | Skr9.25 Million |
| Total Current Liabilities | Skr11.09 Million | Skr3.71 Million | Skr5.08 Million | Skr11.00 Million | Skr9.25 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | Skr-50.61 Million | Skr-1.88 Million | Skr-29.34 Million | Skr-21.66 Million |
| Total Stockholder Equity | Skr8.12 Million | Skr48.21 Million | Skr2.12 Million | Skr22.79 Million | Skr20.23 Million |
| Retained Earnings | — | Skr42.34 Million | Skr850.00K | Skr21.73 Million | Skr19.53 Million |
Biosergen AS Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Biosergen AS generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Skr-35.53 Million | Skr-16.63 Million | Skr-32.60 Million | Skr-29.44 Million | Skr-37.75 Million |
| Capital Expenditures | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 |
| Free Cash Flow | Skr-35.53 Million | Skr-16.63 Million | Skr-32.60 Million | Skr-29.44 Million | Skr-37.75 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | Skr65.36 Million | Skr5.14 Million | Skr37.12 Million | Skr58.83 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | — | — | — | — | — |
| Change in Cash | Skr-35.57 Million | Skr48.73 Million | Skr-27.46 Million | Skr7.68 Million | Skr21.08 Million |
Biosergen AS Earnings History — EPS Actual vs. Analyst Estimates
Track Biosergen AS's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 19, 2025 | -5.00 | -2.00 | -150.00% |
| Aug 20, 2025 | -5.00 | -2.00 | -150.00% |
| May 21, 2025 | -2.00 | -2.00 | +0.00% |
| Mar 05, 2025 | -2.00 | 0.00 | — |
| Nov 08, 2024 | -0.03 | — | — |
| Aug 30, 2024 | -4.00 | — | — |
| May 31, 2024 | -5.00 | -10.00 | +50.00% |
| Feb 29, 2024 | -0.08 | — | — |